ArQule Message Board - Msg: 9076047

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (327)	4/22/1999 10:39:00 AM
From: tommysdad	Read Replies (1) of 399

Can I take a shot at these? 1) Too many biotechs have an uncertain future. By doing deals with these companies, ARQL runs the risk of tying up their best assets (the molecules) with companies that can never take them forward. 2) There is information in negative results, which is surely why Pharma wants "knowledge of the exact compounds". In addition, my understanding is everyone screens the same compounds, so collaborators run the risk of screening compounds someone else has already picked through. Maybe they're shooting for some type of "exclusivity period" for certain libraries? 3) Deals take a long time for the lawyers to pick through, even after the essential details have been agreed upon. The CEO certainly implies they are at that stage. Deals are clearly on the way, I think.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next